MedMira Inc., a prominent player in the health care sector, operates within the Health Care Equipment & Supplies industry. The company is listed on the TSX Venture Exchange and trades in Canadian dollars (CAD). As of November 4, 2025, MedMira Inc. closed at a price of 0.08 CAD per share. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 0.14 CAD on February 11, 2025, and a 52-week low of 0.07 CAD on August 21, 2025.
With a market capitalization of 52,630,000 CAD, MedMira Inc. is a significant entity in its field. However, the company’s financial metrics indicate challenges, as evidenced by a Price Earnings (P/E) ratio of -10.71. This negative P/E ratio suggests that the company is currently not generating profits, which is a critical consideration for investors.
MedMira Inc. is dedicated to the development, manufacturing, and marketing of next-generation rapid diagnostic tests and instrumental equipment. These products are designed to aid in the diagnosis of a wide range of human diseases, both infectious and non-infectious, on a global scale. The company’s focus on innovative diagnostic solutions positions it as a key player in the medical biotechnology landscape, addressing critical needs in healthcare diagnostics.
The company’s strategic initiatives and product offerings are aimed at enhancing diagnostic capabilities worldwide, potentially transforming how diseases are detected and managed. Despite the current financial challenges, MedMira Inc.’s commitment to advancing medical technology underscores its potential for future growth and impact in the healthcare industry.
